Abhayrab Vaccine contains Purified Vero Cell Rabies Vaccine (PVRV) and is used for the prevention and treatment of rabies, both before and after exposure to the virus. This vaccine is developed by cultivating the rabies virus in Vero cells (a type of kidney cell from the African green monkey), followed by a meticulous purification process to eliminate impurities. The virus is then inactivated so it can no longer cause disease, but still triggers the body’s immune system to build protection.
Pre-exposure vaccination is especially recommended for travelers to rabies-endemic regions, individuals with high-risk occupations (such as veterinarians, animal handlers, and lab personnel), and children residing in areas with a high incidence of rabies. Post-exposure prophylaxis (PEP) involves immediate and thorough wound cleansing, followed by a series of vaccine doses, and, in some cases, administration of rabies immunoglobulin or monoclonal antibodies for enhanced protection.
The rabies virus, a member of the Rhabdoviridae family, causes an acute and progressive infection that is almost universally fatal once symptoms appear. However, the disease is entirely preventable if timely and appropriate prophylactic measures are taken using modern vaccines and immunological agents.
The Abhayrab Vaccine is derived from the Pitman-Moore strain of the rabies virus and is produced using Vero cell culture technology, ensuring a high level of purity, safety, and immunogenicity.
Vaccination should be avoided in individuals who have a known hypersensitivity to any component of the Abhayrab Vaccine. In cases of moderate to severe illness, it may be best to postpone vaccination until recovery. However, minor illnesses, such as a common cold, usually do not interfere with the administration of the vaccine